- Home
- XOMAP vs PTCT Comparison
XOMAP vs PTCT Comparison
Compare XOMAP & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOMAP
- PTCT
- Stock Information
- Founded
- XOMAP N/A
- PTCT 1998
- Country
- XOMAP United States
- PTCT United States
- Employees
- XOMAP 13
- PTCT N/A
- Industry
- XOMAP Biotechnology: Pharmaceutical Preparations
- PTCT Biotechnology: Pharmaceutical Preparations
- Sector
- XOMAP Health Care
- PTCT Health Care
- Exchange
- XOMAP Nasdaq
- PTCT Nasdaq
- Market Cap
- XOMAP N/A
- PTCT N/A
- IPO Year
- XOMAP N/A
- PTCT 2013
- Fundamental
- Price
- XOMAP $25.62
- PTCT $50.69
- Analyst Decision
- XOMAP
- PTCT Hold
- Analyst Count
- XOMAP 0
- PTCT 13
- Target Price
- XOMAP N/A
- PTCT $58.85
- AVG Volume (30 Days)
- XOMAP N/A
- PTCT 717.0K
- Earning Date
- XOMAP N/A
- PTCT 02-27-2025
- Dividend Yield
- XOMAP N/A
- PTCT N/A
- EPS Growth
- XOMAP N/A
- PTCT N/A
- EPS
- XOMAP N/A
- PTCT N/A
- Revenue
- XOMAP N/A
- PTCT $900,664,000.00
- Revenue This Year
- XOMAP N/A
- PTCT N/A
- Revenue Next Year
- XOMAP N/A
- PTCT $12.94
- P/E Ratio
- XOMAP N/A
- PTCT N/A
- Revenue Growth
- XOMAP N/A
- PTCT 12.84
- 52 Week Low
- XOMAP N/A
- PTCT $24.00
- 52 Week High
- XOMAP N/A
- PTCT $54.16
- Technical
- Relative Strength Index (RSI)
- XOMAP 47.68
- PTCT 60.36
- Support Level
- XOMAP $25.57
- PTCT $49.57
- Resistance Level
- XOMAP $25.83
- PTCT $52.95
- Average True Range (ATR)
- XOMAP 0.11
- PTCT 2.10
- MACD
- XOMAP -0.01
- PTCT 0.10
- Stochastic Oscillator
- XOMAP 24.24
- PTCT 68.70
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.